HDAC1 and B-cell non-Hodgkin lymphoma: Our study raises the prospect of using selective HDAC1 and HDAC2 inhibitors for the treatment of BL and other B cell lymphomas with Myc deregulation, with possibly less side effects than pan-HDACis currently used.